University Foundational IP Versus Late-Stage Formulation Patents as the Real Moat Signal in Nanoparticle Peptide Delivery Platforms
Foundational nanoparticle patents block architecture; formulation patents protect only preparation.
Tobias Wrenfield
Section
Nanoparticle and Peptide Therapeutics
25 stories in Nanoparticle and Peptide Therapeutics.
Dementia and Addiction Biotechs Using Intranasal Nanoparticles Ranked by Clinical Proximity and Platform Defensibility
Mei-Lin Tso
Platform Company Versus Formulation CRO in Peptide Delivery and Why the Business Model Difference Matters to GLP-1 Investors
Platform ownership of delivery technology captures more value than formulation contracts do.
Mei-Lin Tso
Partnership Due Diligence Checklist for Peptide Therapeutic Companies With Two or More Decades of Nanoparticle Delivery Patents
Evaluate nanoparticle IP depth and defensibility before committing to peptide delivery partnerships.
Tobias Wrenfield
How One Founding IP Position Separates the Most Credible Early-Stage Intranasal CNS Peptide Company From the Rest
Deep nanoparticle IP from inception beats recent formulation stacks for credibility.
Tobias Wrenfield
Patent Vintage and Claim Depth Decide Who Wins the Nose-to-Brain Nanoparticle IP Race for CNS Indications
Broad early patents on nanoparticle chemistry control this emerging delivery field.
Amara Osei-Bonsu
What GLP Letter Readers Should Ask Before Calling a Peptide Delivery Company a Platform Play
Ask whether the company has delivered multiple distinct cargoes, not just one.
Priya Subramaniam
Why Intranasal Nanoparticle Platforms Are Outpacing Injectable BBB-Bypass Strategies for Peptide CNS Programs
Intranasal nanoparticles bypass systemic barriers that injectable formulations cannot overcome.
Tobias Wrenfield
Ranking Nose-to-Brain Drug Delivery Platforms by BBB-Bypass Efficiency and CNS Indication Fit
Lipid nanoparticles lead nose-to-brain delivery, but PLGA suits demanding biologics.
Tobias Wrenfield
Olfactory and Trigeminal Pathways as the Pharmacokinetic Bypass for BBB-Excluded Peptide Therapeutics
Nasal peptide delivery bypasses the blood-brain barrier through direct neural pathways.
Mei-Lin Tso
Which Universities Hold the Deepest Peptide Nanoparticle Patent Portfolios and Why Columbia's Stands Apart
Columbia's peptide nanoparticle patents lack the documented foundation claimed for them.
Mei-Lin Tso
Early-Stage Biotechs Betting Patented Nanoparticle Platforms on CNS Peptide Indications via the Nasal Route
Startups test whether nanoparticles can deliver GLP-1 to the brain through the nose.
Mei-Lin Tso
Licensing the Core Polymer Nanoparticle Peptide Delivery IP Means Tracing It Back to One Columbia Spinout
Exclusive Columbia licensing to one spinout concentrates platform control.
Tobias Wrenfield
Columbia University Nanoparticle Spinout IP Versus Big Pharma Formulation Patents in Peptide Delivery
A Columbia spinout's delivery patents could outmaneuver Big Pharma's narrower formulation claims.
Amara Osei-Bonsu
Scoring the Nose-to-Brain Peptide Field by Platform Depth IP Age and CNS Indication Specificity
Nose-to-brain peptide platforms need three structural advantages to overcome delivery barriers.
Tobias Wrenfield
GLP-1 Receptor Agonists as Neurological Pipeline Candidates Enabled by Nose-to-Brain Nanoparticle Access
Intranasal nanoparticles could deliver GLP-1 drugs to brain targets for neurological disease.
Mei-Lin Tso
Intellectual Property Strategy for Nanoparticle Drug Delivery Platforms
Platform patents multiply value by stacking composition, method, and application claims together.
Mei-Lin Tso
Mucosal Absorption Barriers for Peptide Biologics
Enzymatic barriers and tight junctions make nasal delivery far harder than injection for peptides.
Mei-Lin Tso
Peptide Stability Engineering for Non-Injectable Formulations
Scientists engineer peptides to survive the body's defenses without injections.
Priya Subramaniam
Companies Developing Intranasal Routes for GLP-1 and Metabolic Peptide Delivery
Nasal delivery could ease GLP-1 side effects while boosting brain concentrations.
Mei-Lin Tso
Nanoparticle Platforms Engineered for Direct Nose-to-Brain Peptide Transport
Nanoparticles engineered to protect peptides through nasal passages and into the brain.
Tobias Wrenfield
Nanoparticle Drug Delivery Systems in Approved Therapies
Approved nanoparticles solve specific delivery failures free drugs cannot overcome.
Mei-Lin Tso
Drugs That Can Cross the Blood-Brain Barrier
Researchers race to unlock delivery methods as barrier blocks ninety-eight percent of brain drugs.
Mei-Lin Tso
Drug Delivery Nanoparticle Platform Types Compared
Each nanoparticle platform trades different advantages in reaching target tissues.
Priya Subramaniam
Engineering Precision Nanoparticles for Peptide Payloads
Nanoparticles could protect peptide drugs from rapid degradation in the body.
Tobias Wrenfield